Epithelial ovarian cancer has the highest mortality rate of all gynaecological malignancies.
There is a high expression of VEGFR in ovarian cancer and many tumours produce high levels of VEGF. Inhibitors of VEGF signalling such as the recombinant monoclonal antibody, bevacizumab that binds to circulating VEGF-A and aflibercept, a fusion protein that binds directly to VEGF preventing it from binding to its receptors, have been extensively evaluated in ovarian cancer treatment. Another strategy that has been explored is to use a peptide-Fc fusion protein, trebananib, which binds to Ang 1 and Ang 2, preventing its interaction with the Tie 2 receptor [3].
Bevacizumab
In ovarian cancer, bevacizumab has been explored as a single agent, in combination with chemotherapy, and as maintenance treatment post chemotherapy. It has been studied extensively in the setting of first-line platinum-based chemotherapy, 'platinum-sensitive' (relapse > 6months following completion of platinum based treatment) and in 'platinumresistant' disease (relapse ≤6 months of completing platinum based treatment). For a summary the pivotal trials described below see table 1. ICON7 [9] and GOG 218 [10] are the two key first-line studies investigating the addition of bevacizumab to chemotherapy following surgery for advanced ovarian cancer. In ICON7, patients were randomised to standard 6 cycles of three-weekly carboplatin and paclitaxel with or without intravenous bevacizumab 7.5mg/kg every three weeks followed by maintenance bevacizumab for up to 12 months. The median progression free survival (PFS) was 17.5 months with standard therapy alone versus 19.9 months in the bevacizumab arm (HR 0.87;  p=0.04). The benefit from bevacizumab was greater in women at higher risk of progression due to incomplete cytoreductive surgery ( ≥1 cm residual disease) or FIGO stage IV disease. 5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   7 In women with 'platinum-resistant' relapse, the phase III randomised AURELIA trial [15] evaluated the addition of bevacizumab to a choice of chemotherapy regimens (weekly paclitaxel, pegylated liposomal doxorubicin [PLD] or topotecan, given either over five days, or weekly). Overall, there was a 3.3month improvement in median PFS when bevacizumab was added to chemotherapy which was significant (table 1). Bevacizumab was not continued as maintenance therapy but the benefit in PFS and quality of life was seen consistently across all subgroups, particularly in patients with ascites, which is associated with a poorer prognosis [16] . The greatest difference in PFS was seen in patients receiving weekly paclitaxel [17] . There was no statistically significant improvement in OS but the trial was not designed to show a difference in OS and 40% of patients receiving chemotherapy alone were subsequently treated with bevacizumab.
Toxicities of VEGF-Inhibitors include hypertension, impaired wound healing, proteinuria, increase risk of thromboembolism and gastrointestinal toxicities. This includes the rare but serious complications of perforation and fistulae and a decision to use bevacizumab needs to take note of the volume of serosal disease, particularly thickening of the sigmoid colon due to tumour, as the risk of perforation is greater in patients with large amounts of serosal disease.
Despite evidence of activity in different phases of the treatment pathway, there is no international consensus about when the value of bevacizumab therapy is greatest. This is reflected in the license, with indications varying across the world. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 9
Multi-targeted anti-angiogenic agents
Tyrosine kinase inhibitors (TKIs) are multi-targeted, low-molecular weight drugs, which bind to the ATP-binding catalytic site of the tyrosine kinase domains of VEGF-R and other tyrosine kinases. These oral agents often target more than one receptor tyrosine kinase [4] .
Examples include sorafenib, cediranib, pazopanib and nintedinib, all of which have been shown to have activity in ovarian cancer [3] . It is attractive to use a drug that targets more than one pathway, as this could lead to a greater inhibition of angiogenesis compared with single pathway inhibitors such as bevacizumab. However, while the therapeutic response may be greater, their more complex mechanism of action may increase toxicity [4] (table 2).
Pazopanib
Pazopanib targets several angiogenic receptors including downstream signals of VEGFR 1, 2, 3, 23] . Pazopanib has been evaluated in recurrent ovarian cancer and as maintenance therapy in the first-line setting. In MITO11 [24] , an open-label phase II trial, patients with 'platinum-resistant' ovarian cancer were randomised to weekly paclitaxel with or without pazopanib. There was a 2.9 month improvement in PFS in the combination arm (median 6.3 vs 3.4 months) that was statistically significant. In the phase III study, AGO-OVAR-16, patients who did not have tumour progression at the end of first-line therapy, were randomised to maintenance pazopanib or placebo for up to 24 months. There was an improvement of 5.6 months in the median PFS in patients on pazopanib compared to placebo, however this did not translate into an OS benefit and there were much higher grade 3/4 adverse event rates in patients on pazopanib, for example, hypertension, neutropenia, liver toxicity, diarrhoea, fatigue, thrombocytopenia and palmar-plantar erythema. The dose of 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 11 allowed comparison of the effect of cediranib with chemotherapy, and as maintenance therapy [30] . The original trial design was changed when the manufacturer temporarily ceased production of the drug, and the main comparison using a smaller number of patients was between chemotherapy and concurrent cediranib followed by maintenance cediranib with chemotherapy and placebo throughout. There was a significant improvement in median PFS, from 8.7 to 11 months (HR 0.56; p<0.0001) . OS data were immature at the time of publication. However, toxicity, principally fatigue, diarrhoea and hypertension were significant with 32% of patients discontinuing cediranib during treatment. This was most evident when cediranib was given with chemotherapy [30] . A submission for Market Authorisation in patients was recently withdrawn by the manufacturer. However, cediranib is an active drug and continues to be evaluated in ovarian cancer (see below).
Targeting the folate receptor
The folate cycle maintains essential metabolic reactions required for rapidly growing cells.
Once folates enter a cell, they have a crucial role in the biosynthesis of purines and thymidine, required for DNA synthesis, repair and methylation [31] [32] [33] [34] . The alpha isoform of the FR (αFR) transports folates by receptor-mediated endocytosis [35] and is selectively overexpressed in a number of solid tumours, including non-mucinous ovarian cancers [36] Farletuzumab (MORAb-003), a humanised monoclonal antibody to αFR leads to cellmediated cytotoxicity, complement dependent killing and non-immune mediated αFR-dependent inhibition of growth under folate limiting conditions [36, 37] . An initial phase II study looking at the addition of farletuzumab to chemotherapy followed by maintenance therapy in 'platinum-sensitive' ovarian cancer showed promising activity with an improved 12 overall response rate compared to historical controls [38] . However, the benefit was not confirmed in a subsequent phase III trial [39] .
In a different folate-targeting strategy, vintafolide (EC145), a folate-conjugated vinca alkaloid that targets FR-expressing cells was explored in a randomised phase II trial in 'platinum-resistant' ovarian cancer. In the PRECEDENT trial patients were randomised to PLD alone, or in combination with vintafolide [40] . The study met its primary end point, demonstrating a 2.3 month improvement in median PFS in the experimental arm (5.0 versus 2.7 months; HR 0.63; p=.031]) but the subsequent randomised phase III trial (PROCEED)
[41] was stopped early because a pre-specified interim analysis showed no benefit.
Homologous recombination deficiency (HRD) and ovarian cancer
Normal cellular function and genomic stability is maintained by recognition and subsequent repair of DNA damage that occurs in all cells [42] . There are 450 known genes implicated in DNA damage response and repair [43] and they are sub-divided into 5 distinct pathways which are responsible for repair of specific types of DNA damage [44] . Double stranded DNA breaks (DSB) are the most lethal insult to the genome and if left unrepaired, genomic instability and cell death will occur [45] . They can be repaired by several different pathways, the main one being homologous recombination repair (HRR). A large proportion of DSB arise during DNA replication when a replication fork encounters an unrepaired single strand break (SSB). The HRR pathway, together with PARP-1, a nuclear enzyme, is especially important in repairing these collapsed replications forks [46, 47] patients who had received ≥ 3 lines for chemotherapy for ovarian cancer and the overall response rate was 34%, median duration of response 7.9 months [58] .On the basis of these data the US FDA granted approval for single agent olaparib in this group.
Olaparib maintenance therapy
Most of the studies with olaparib and other PARPi have focussed on using these drugs as maintenance therapy following chemotherapy. The original trial, study 19, included patients with platinum-sensitive HGSOC who had responded to platinum-based therapy. and it remains to be seen whether the sensitivity of this assay is sufficient for it to distinguish patients who may or may not have a clinically meaningful benefit from niraparib. The most common adverse effects were thrombocytopenia, often occurring early, anaemia and neutropenia, which could usually be managed by dose reductions.
As with olaparib, combination studies of niraparib with bevacizumab have started and there are plans to conduct studies in the first-line setting. The drug has yet to be licensed in ovarian cancer, but the results of the NOVA trial have confirmed the significant benefit of PARPi in 20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 21 unselected patients with heavily pre-treated 'platinum-resistant' ovarian cancer patients were enrolled, making this the largest reported dataset of patients with ovarian cancer and immune checkpoint inhibitors. The overall response rate was 9.7% [88] . The most common treatment related adverse events were fatigue, nausea/vomiting, diarrhoea/constipation, chills, infusion-related reactions, rash and hypothyroidism. Whilst tumour response rates are modest, some patients experience long responses to all these checkpoint inhibitors. Phase III trials with avelumab in ovarian cancer are currently underway. JAVELIN Ovarian 200 (NCT02580058) is a trial of avelumab +/-PLD vs PLD alone in 'platinum-resistant' ovarian cancer and JAVELIN Ovarian 100 (NCT02718417) is a three-arm trial evaluating avelumab in combination with and/or following first line chemotherapy for advanced ovarian cancer.
Phosphatidylinositol 3-Kinase (PI3K) inhibitors
The PI3K/AKT/mTOR is a complex pathway that regulates a number of crucial cellular functions, including cell growth, migration, survival and angiogenesis [89] . Changes in the pathway and molecular alterations, such as gene mutations and amplifications contribute to oncogenesis and resistance to anti-cancer drugs. It is an important therapeutic target in cancer, however, there has been little success of these agents in ovarian cancer to date [90] .
Wee1 inhibitors
When DNA is damaged, there are various checkpoints that arrest the cell cycle to allow for this damage to be repaired. The G1 checkpoint is mainly regulated by the p53, which is commonly mutated in cancer cells. p53-deficient tumours therefore rely on the G2/S checkpoint for DNA damage repair [91] . If the G2 checkpoint is impeded, then p53 deficient cells may become more sensitive to DNA-damaging drugs [92] . Wee1 is a tyrosine kinase that phosphorylates CDC2, which inactivates the CDC2/cyclin B complex required for the 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 22 normal functioning of the G2 checkpoint. AZD1775 (formally MK-1775) is a potent Wee1 inhibitor. In combination with carboplatin, it has been shown to have promising activity in 'platinum-resistant' disease (relapse <3 months following completion of first line therapy) with p53 mutations. The most common toxicities reported were myelosuppression, fatigue, diarrhoea, nausea and vomiting [93] .
Summary
This review highlights the paradigm shift in the treatment of ovarian cancer. Although chemotherapy remains the backbone of treatment, novel targeted therapies, both in combination with chemotherapy and alone, have demonstrated significant improvements in PFS and the 'one size fits all' treatment approach for ovarian cancer is no longer applicable.
Bevacizumab are olaparib are two drugs directed against the angiogenic and DNA damage response pathways that have been approved for treatment of ovarian cancer. Olaparib is the first drug directed against a predictive marker which allows the selection of patients likely to achieve the greatest benefit. Encouraging results are emerging from studies with other PARP inhibitors and these are likely to widen the use of these drugs in ovarian cancer. A benefit is seen not only in patients with a BRCA mutation, but also in a larger number of patients within an HRD positive group. Combinations of PARP inhibitors with other molecularly targeted therapies, especially anti-angiogenic drugs are also showing promise. The most recent development in therapeutics has been investigation of immune checkpoint inhibitors.
Their role in treatment of ovarian cancer is unclear, but many trials are in progress and there is hope that the benefit of these drugs seen in other tumours may extend into the treatment of ovarian cancers. 3 arm study: CT with placebo vs CT + cediranib followed by placebo maintenance vs CT + cediranib followed by cediranib maintenance  There are no predictive markers for benefit but one trial, ICON7 in the first-line setting demonstrated a survival benefit in patients with a poorer prognosis.
 In 'platinum-resistant' disease, the addition of bevacizumab to chemotherapy improves the tumour response rate, progression-free survival and patient-reported outcomes.
 BRCA mutations are the first predictive markers for response to PARP inhibitors in ovarian cancer. Olaparib is the first-in-class drug to be licensed for the treatment of ovarian cancer as maintenance therapy in platinum-sensitive ovarian cancer with a BRCA mutation. 
